Diacerein versus adipoRon as adiponectin modulators in experimentally-induced end-stage type 2 diabetes mellitus in rats

The objective of the present study is to evaluate and compare the possible anti-diabetic effects of adipoRon and diacerein in type 2 diabetes mellitus (T2DM) rats. T2DM is marked by impaired oxidative, inflammatory and metabolic signaling. Indeed, T2DM progression is associated with elevated HbA1C%, low adiponectin and insulin concentration. Moreover, in this study epididymal adipose tissue and soleus muscle MDA contents significantly escalated, while serum TAC and epididymal adipose Nrf2 significantly declined. Nevertheless, serum TNF-alpha, epididymal NLRP3, NF-kappa B, PPAR gamma and CD68 expression rose significantly with a parallel significant reduction in serum IL-10 and soleus muscle expression of IRS1. Both adipoRon and diacerein significantly improved adiponectin and insulin secretion with augmentation of anti-oxidant defenses and diminution of oxidative burden, with obvious anti-inflammatory consequences (p < 0.05). Thus, adipoRon and diacerein positively modulated adiponectin expression with down-regulation of NF-kappa B/NLRP3/PPAR gamma expression with subsequent improvement in glycemic control, inflammatory and oxidative signaling.

Automated summary

This study evaluated and compared the anti-diabetic effects of adipoRon and diacerein in type 2 diabetes mellitus rats, finding that both substances can improve adiponectin and insulin secretion, enhance antioxidant defenses, reduce oxidative burden, and have significant anti-inflammatory effects.